RareCyte will use the SOPHiA DDM™ Platform to support its oncology testing panel BOSTON and ROLLE, Switzerland, Jan. 18, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that RareCyte Inc., a precision biology company based in Seattle, Washington, is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM™ Platform to complement its  Precision Biology Services portfolio. RareCyte is an innovative precision bi ...

SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care in India BOSTON and ROLLE, Switzerland, Jan. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Karkinos Healthcare, a purpose-driven cancer care technology network based in India, will partner with SOPHiA ...

Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform continue to grow year-over-year, with Tennessee Oncology, Dasa and The Royal Marsden announced today BOSTON and ROLLE, Switzerland, Jan. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, will share an overview of its near-term growth strategy, fueled by strong adoption and opportunity for the SOPHiA ...

Insights from multimodal datasets on the platform fuel cancer research in Canada BOSTON and ROLLE, Switzerland, Jan. 8, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced a collaboration with Exactis Innovation, based in Montreal, Quebec, who will contribute to cancer research and data-driven decision-making through SOPHiA GENETICS' multimodal real-world data offering. Exactis Innovation is a non-profit network of hospit ...

The Hospital will use SOPHiA GENETICS technology to streamline workflows and expedite research BOSTON and ROLLE, Switzerland, Dec. 21, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2023 Results Conference Call November 7, 2023 8:00 AM ET Company Participants Katherine Bailon - Head, IR Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - CFO and COO Conference Call Participants Yuko Oku - Morgan Stanley Kyle Boucher - TD Cowen Mark Massaro - BTIG Operator Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today. At this time, I would like to welcome everyone to the SOPHiA GENETICS Third Quarter ...

[Unaudited Interim Condensed Consolidated Financial Statements](index=2&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Financial%20Statements) [Unaudited Interim Condensed Consolidated Statements of Loss](index=3&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Loss) Revenue grew **32.6%** to **$45.3 million**, with net loss decreasing **25.3%** to **$54.9 million** Consolidated Statement of Loss Highlights (in USD thousands) | Metric | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | YoY Change | | :--- | :--- | :--- | :--- | | **Revenue** | $45,323 | $34,176 | +32.6% | | **Gross Profit** | $31,014 | $21,624 | +43.4% | | **Operating Loss** | $(55,879) | $(72,739) | -23.2% | | **Loss for the period** | $(54,920) | $(73,478) | -25.3% | | **Basic and diluted loss per share** | $(0.85) | $(1.15) | -26.1% | [Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss](index=4&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) Total comprehensive loss improved to **$52.9 million**, driven by reduced net loss and positive currency translation Consolidated Statement of Comprehensive Loss (in USD thousands) | Metric | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Loss for the period | $(54,920) | $(73,478) | | Currency translation differences | $2,269 | $(10,249) | | **Total comprehensive loss for the period** | **$(52,934)** | **$(81,274)** | [Unaudited Interim Condensed Consolidated Balance Sheets](index=5&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to **$205.9 million** due to reduced cash, with liabilities rising and equity falling to **$158.4 million** Key Balance Sheet Items (in USD thousands) | Asset/Liability/Equity | September 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $132,767 | $161,305 | | Total assets | $205,852 | $243,838 | | Total liabilities | $47,413 | $43,708 | | Total equity | $158,439 | $200,130 | [Unaudited Interim Condensed Consolidated Statements of Changes in Equity](index=6&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Equity) Total equity decreased from **$200.1 million** to **$158.4 million**, primarily due to a **$54.9 million** net loss Equity Reconciliation for Nine Months Ended Sep 30, 2023 (in USD thousands) | Description | Amount | | :--- | :--- | | Equity as of January 1, 2023 | $200,130 | | Loss for the period | $(54,920) | | Other comprehensive income | $1,986 | | Share-based compensation | $11,036 | | Other transactions with owners | $207 | | **Equity as of September 30, 2023** | **$158,439** | [Unaudited Interim Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities improved to **$37.3 million**, with cash decreasing to **$132.8 million** Net Cash Flow Summary (in USD thousands) | Cash Flow Activity | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Net cash flows used in operating activities | $(37,283) | $(59,764) | | Net cash flow provided from investing activities | $10,569 | $29,835 | | Net cash flow used in financing activities | $(2,311) | $(988) | | **Cash and cash equivalents at end of the period** | **$132,767** | **$157,827** | [Notes to the Unaudited Interim Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20the%20Unaudited%20Interim%20Condensed%20Consolidated%20Financial%20Statements) Detailed disclosures cover company background, accounting policies, revenue, balance sheet, and income statement items [Note 1: Company Information](index=9&type=section&id=1.%20Company%20information) SOPHiA GENETICS SA, a Swiss cloud-native software company, reduced D&O insurance cash from **$30 million** to **$15 million** - The company is a cloud-native software company in the healthcare space, commercializing its SOPHiA DDM™ platform for analyzing complex multimodal datasets[17](index=17&type=chunk) - In June **2023**, the company reduced the designated cash set aside for its Directors and Officers Insurance Policy from **$30 million** to **$15 million**[24](index=24&type=chunk) - As of September **30**, **2023**, the company held **11,766,158** treasury shares, a significant increase from **2,257,163** held a year prior, primarily for administering equity incentive programs[33](index=33&type=chunk) [Note 2: Fair Value](index=11&type=section&id=2.%20Fair%20Value) Financial assets and liabilities' carrying amounts approximate fair values as of September **30**, **2023**, with no significant changes - The carrying amount of financial assets and liabilities, including cash, accounts receivable, and accounts payable, is a reasonable approximation of their fair value as of September **30**, **2023**[35](index=35&type=chunk) [Note 3: Financial Risk Management](index=12&type=section&id=3.%20Financial%20Risk%20Management) The company faces credit, liquidity, and market risks, with no significant changes in risk management since year-end **2022** - The company is exposed to credit, funding, liquidity, and market risks, with no significant changes in its risk management approach since December **31**, **2022**[36](index=36&type=chunk) [Note 4: Segment Reporting](index=12&type=section&id=4.%20Segment%20Reporting) The company operates as a single segment, with the CEO reviewing financial information on a consolidated basis - The company operates in a single operating segment, and its performance is assessed as a whole by the senior management team led by the CEO[37](index=37&type=chunk) [Note 5: Revenue](index=12&type=section&id=5.%20Revenue) Revenue primarily from SOPHiA DDM™ Platform, with EMEA contributing **71%** and NORAM **16%**, both showing strong growth Revenue by Geographic Region (in USD thousands) | Region | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | YoY Growth | | :--- | :--- | :--- | :--- | | EMEA | $32,378 | $25,288 | +28.0% | | NORAM | $7,268 | $4,656 | +56.1% | | LATAM | $3,062 | $2,189 | +39.9% | | APAC | $2,615 | $2,043 | +28.0% | | **Total** | **$45,323** | **$34,176** | **+32.6%** | Revenue by Stream (in USD thousands) | Revenue Stream | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | SOPHiA DDM Platform | $44,331 | $32,884 | | Workflow equipment and services | $992 | $1,292 | [Note 6: Accounts Receivable](index=13&type=section&id=6.%20Accounts%20receivable) Net accounts receivable increased to **$9.8 million** from **$6.6 million**, driven by a rise in accrued contract revenue Accounts Receivable Breakdown (in USD thousands) | Component | September 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Accounts receivable | $4,631 | $6,060 | | Accrued contract revenue | $6,064 | $1,499 | | Allowance for expected credit losses | $(1,056) | $(1,095) | | **Net accounts receivable** | **$9,781** | **$6,649** | [Note 7: Loss Per Share](index=13&type=section&id=7.%20Loss%20per%20share) Loss per share improved to **$0.85** from **$1.15** for the nine months ended September **30**, **2023**, on **64.6 million** shares Loss Per Share Calculation | Metric | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Net loss attributed to shareholders (USD thousands) | $(54,920) | $(73,478) | | Weighted average number of shares in issue | 64,607,758 | 64,058,859 | | **Basic and diluted loss per share** | **$(0.85)** | **$(1.15)** | [Note 8: Leases](index=14&type=section&id=8.%20Leases) In June **2023**, a **108**-month lease for new R&D office space in France recorded a **$2.3 million** right-of-use asset and liability - On June **1**, **2023**, the company entered into a **108**-month lease for office space in Bidart, France, to support R&D expansion, recording a right-of-use asset and lease liability of **$2.3 million**[43](index=43&type=chunk) [Note 9: Borrowings](index=14&type=section&id=9.%20Borrowings) A revolving credit facility of up to **CHF 5.0 million** with Credit Suisse had no outstanding borrowings as of September **30**, **2023** - The company has a credit facility of up to **CHF 5.0 million** with Credit Suisse, with no borrowings outstanding as of September **30**, **2023**[44](index=44&type=chunk) [Note 10: Share-based Compensation](index=14&type=section&id=10.%20Share-based%20compensation) Share-based compensation expense totaled **$11.04 million**, consistent with prior year, largely from general and administrative functions Share-based Compensation Expense (in USD thousands) | Department | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Research and development | $2,489 | $1,732 | | Sales and marketing | $794 | $1,175 | | General and administrative | $7,753 | $8,110 | | **Total** | **$11,036** | **$11,017** | [Note 11: Related Party Transactions](index=14&type=section&id=11.%20Related%20party%20transactions) Key management compensation increased to **$11.0 million** from **$9.1 million**, driven by higher salaries and share-based compensation Key Management Compensation (in USD thousands) | Compensation Type | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Salaries and other short-term benefits | $2,814 | $1,613 | | Share-based compensation expense | $7,713 | $7,061 | | **Total** | **$10,994** | **$9,109** | [Note 12: Events After the Reporting Date](index=15&type=section&id=12.%20Events%20after%20the%20reporting%20date) No material subsequent events requiring recognition or disclosure were identified after the reporting date through November **7**, **2023** - There were no material events after the reporting date that required recognition or disclosure in the financial statements[49](index=49&type=chunk)

SOPHiA GENETICS SA (NASDAQ:SOPH) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Katherine Bailon - Head, Investor Relations Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - Chief Financial Officer and COO Conference Call Participants Edmund Tu - Morgan Stanley Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Vidyun Bais - BTIG Operator Hello, ladies and gentlemen. And thank you for joining SOPHiA GENETICS Second Quarter 2020 Earnings Call. Our host for today is Katherin ...

Table of Contents | | Unaudited Interim Condensed Consolidated Financial Statements | F-2 | | --- | --- | --- | | – | Unaudited Interim Condensed Consolidated Statements of Loss | F-3 | | – | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss | F-4 | | – | Unaudited Interim Condensed Consolidated Balance Sheets | F-5 | | – | Unaudited Interim Condensed Consolidated Statements of Changes in Equity | F-6 | | – | Unaudited Interim Condensed Consolidated Statements of Cash Flows | F-8 | | ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Katherine Bailon - Vice President of Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - Chief Financial Officer and Chief Operating Officer Conference Call Participants Tejas Savant - Morgan Stanley Marta Nazarovets - JPMorgan Chase & Co. Kyle Boucher - TD Cowen Operator Good morning, and welcome to the SOPHiA GENETICS' First Quarter 2023 Earnings Conference Call ...